A 2019 spin-out of the Max-Planck-Institute of Colloids and Interfaces has raised additional seed finance from a venture capital syndicate to progress antibody treatments for cancer. Tacalyx GmbH announced the funding on 11 June which increases its seed finance to more than €14 million. The company is developing antibody therapeutics that target tumour associated carbohydrate antigens. These are glycan structures often found on cancer cells but which don’t usually appear on other tissues.
